Figure 2.

A, Event Free Survival of CLL patients who started therapy with ibrutinib at ≥2.5 mg/kg daily dose compared to <2.5 mg/kg daily dose. B, Overall Survival of CLL patients who started therapy with ibrutinib at ≥2.5 mg/kg daily dose compared to <2.5 mg/kg daily dose